IL240894B - Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses - Google Patents

Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses

Info

Publication number
IL240894B
IL240894B IL240894A IL24089415A IL240894B IL 240894 B IL240894 B IL 240894B IL 240894 A IL240894 A IL 240894A IL 24089415 A IL24089415 A IL 24089415A IL 240894 B IL240894 B IL 240894B
Authority
IL
Israel
Prior art keywords
decitabine
kits
derivatives
compositions
combinations
Prior art date
Application number
IL240894A
Other languages
English (en)
Hebrew (he)
Other versions
IL240894A0 (en
Original Assignee
Astex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Pharmaceuticals Inc filed Critical Astex Pharmaceuticals Inc
Publication of IL240894A0 publication Critical patent/IL240894A0/en
Publication of IL240894B publication Critical patent/IL240894B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL240894A 2013-03-01 2015-08-27 Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses IL240894B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771525P 2013-03-01 2013-03-01
US201361887165P 2013-10-04 2013-10-04
PCT/US2014/019137 WO2014134355A1 (en) 2013-03-01 2014-02-27 Drug combinations

Publications (2)

Publication Number Publication Date
IL240894A0 IL240894A0 (en) 2015-10-29
IL240894B true IL240894B (en) 2020-10-29

Family

ID=50288308

Family Applications (2)

Application Number Title Priority Date Filing Date
IL240894A IL240894B (en) 2013-03-01 2015-08-27 Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses
IL277385A IL277385A (en) 2013-03-01 2020-09-15 Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL277385A IL277385A (en) 2013-03-01 2020-09-15 Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses

Country Status (24)

Country Link
US (2) US20160015805A1 (enExample)
EP (2) EP2961388B1 (enExample)
JP (2) JP6514647B2 (enExample)
KR (1) KR20150125963A (enExample)
CN (2) CN105025884B (enExample)
AU (1) AU2014223348B2 (enExample)
CA (1) CA2902433A1 (enExample)
CY (1) CY1122554T1 (enExample)
DK (1) DK2961388T3 (enExample)
ES (1) ES2734023T3 (enExample)
HR (1) HRP20191171T1 (enExample)
HU (1) HUE044430T2 (enExample)
IL (2) IL240894B (enExample)
LT (1) LT2961388T (enExample)
MX (2) MX366967B (enExample)
PH (2) PH12015501905A1 (enExample)
PL (1) PL2961388T3 (enExample)
PT (1) PT2961388T (enExample)
RU (2) RU2708246C2 (enExample)
SA (1) SA515360959B1 (enExample)
SG (2) SG11201506727RA (enExample)
SI (1) SI2961388T1 (enExample)
WO (1) WO2014134355A1 (enExample)
ZA (2) ZA201506150B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
JP6626085B2 (ja) * 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
WO2016056596A1 (ja) 2014-10-07 2016-04-14 日本電気株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2016061231A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
WO2016100851A1 (en) 2014-12-18 2016-06-23 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US10526388B2 (en) 2015-03-09 2020-01-07 Cytlimic Inc. Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
AU2016244570B2 (en) * 2015-04-07 2020-08-27 Nec Corporation Medicine
WO2017004538A1 (en) * 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
GB201704966D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
EP3727374A4 (en) * 2017-12-21 2021-11-10 Merck Patent GmbH COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
CN108948203B (zh) * 2018-08-09 2019-06-04 南京鼓楼医院 抗pd-1单克隆抗体及其制备方法和应用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
MX2022013063A (es) * 2020-04-24 2022-12-08 Genexine Inc Metodo para tratamiento del cancer cervicouterino.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US20030148973A1 (en) 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
JP2005528901A (ja) * 2002-06-10 2005-09-29 アバクス・テクノロジーズ・インコーポレーテッド ハプテン化腫瘍細胞の凍結保存
WO2005033278A2 (en) 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
ES2322172T3 (es) * 2004-05-26 2009-06-17 Biovaxim Limited Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas.
AU2005300315A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006076508A2 (en) * 2005-01-14 2006-07-20 Avax Technologies, Inc. Method for producing a vaccine for the treatment of cancer
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PL1928492T3 (pl) * 2005-09-01 2011-09-30 Celgene Corp Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP2451461A4 (en) * 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
KR20130096731A (ko) 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
RU2623161C2 (ru) * 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
HUE042327T2 (hu) * 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
EP2958571B1 (en) * 2013-02-21 2024-04-10 Michele Maio Dna hypomethylating agents for cancer therapy

Also Published As

Publication number Publication date
SA515360959B1 (ar) 2019-04-03
NZ711757A (en) 2020-09-25
LT2961388T (lt) 2019-08-26
DK2961388T3 (da) 2019-07-08
EP2961388A1 (en) 2016-01-06
MX366967B (es) 2019-07-31
AU2014223348A1 (en) 2015-09-03
SI2961388T1 (sl) 2019-10-30
KR20150125963A (ko) 2015-11-10
RU2708246C2 (ru) 2019-12-05
HK1219663A1 (en) 2017-04-13
PH12019550222A1 (en) 2021-10-04
EP2961388B1 (en) 2019-04-24
MX2015011147A (es) 2016-04-28
CY1122554T1 (el) 2021-01-27
JP2019142911A (ja) 2019-08-29
US20160015805A1 (en) 2016-01-21
MX2019008822A (es) 2019-09-26
HRP20191171T1 (hr) 2019-10-04
ZA201506150B (en) 2019-11-27
IL240894A0 (en) 2015-10-29
SG10201707135RA (en) 2017-10-30
RU2015141628A3 (enExample) 2018-03-07
WO2014134355A1 (en) 2014-09-04
AU2014223348B2 (en) 2018-12-13
JP6514647B2 (ja) 2019-05-15
PH12015501905A1 (en) 2016-01-11
JP2016510030A (ja) 2016-04-04
IL277385A (en) 2020-11-30
RU2019138702A (ru) 2020-01-27
US20200009247A1 (en) 2020-01-09
RU2015141628A (ru) 2017-04-06
ZA201905426B (en) 2022-07-27
CA2902433A1 (en) 2014-09-04
ES2734023T3 (es) 2019-12-03
SG11201506727RA (en) 2015-09-29
PL2961388T3 (pl) 2019-10-31
HUE044430T2 (hu) 2019-10-28
CN110448566A (zh) 2019-11-15
NZ750690A (en) 2020-09-25
CN105025884A (zh) 2015-11-04
PT2961388T (pt) 2019-07-11
EP3563836A1 (en) 2019-11-06
CN105025884B (zh) 2019-08-20

Similar Documents

Publication Publication Date Title
IL277385A (en) Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
EP3043824A4 (en) Modified therapeutic agents and compositions thereof
PT2755473T (pt) Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações
IL265876A (en) Preparations that include 15-ohepa and methods of using them
EP3030266A4 (en) Topical compositions and methods of using the same
IL234014A0 (en) Cycloalkane derivatives, preparations containing them and their uses
CA3284288A1 (en) Topical compositions and methods of using the same
IL241355A0 (en) Pyrazole-amide compounds, preparations containing them and their uses
EP2968474A4 (en) SKIN COMPOSITIONS AND USES
EP3039131C0 (en) ENZYME COMPOSITION AND USES
ZA201509262B (en) Tuberculosis compositions and methods of using the same
CL2015001116A1 (es) Composición y uso de dimeros de alquil cetena hidrogenados.
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
IL241359A0 (en) Converted indole-5-ol derivatives, preparations containing them and their uses
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
PL2961822T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
GB2533234B (en) Ocular composition and kits thereof
EP2967055A4 (en) BIOCIDAL COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE
PL2989192T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
SG11201601921RA (en) Azeotrope-like compositions of fo-e-1,3,4,4,4-pentafluoro-3-trifluoromethyl-1-butene and e-1-chloro-3,3,3-trifluoropropene and uses thereof
EP2995294A4 (en) Bathing agent composition
BR112016008035A2 (pt) composição, uso da composição

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed